The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects

Increasing evidence suggests that motor rehabilitation may delay Parkinson’s disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum leve...

Full description

Saved in:
Bibliographic Details
Published inCanadian journal of physiology and pharmacology Vol. 94; no. 4; pp. 455 - 461
Main Authors Angelucci, Francesco, Piermaria, Jacopo, Gelfo, Francesca, Shofany, Jacob, Tramontano, Marco, Fiore, Marco, Caltagirone, Carlo, Peppe, Antonella
Format Journal Article
LanguageEnglish
Published Canada NRC Research Press 01.04.2016
Canadian Science Publishing NRC Research Press
Subjects
Activities of Daily Living
Aged
BDNF
Brain
Brain-derived neurotrophic factor
Brain-Derived Neurotrophic Factor - blood
Care and treatment
exercice physique
Female
Gait - physiology
Humans
maladie de Parkinson
Male
Mental health care
Middle Aged
Motor Activity - physiology
motor rehabilitation
Parkinson Disease - blood
Parkinson Disease - physiopathology
Parkinson's disease
Patient outcomes
physical exercise
Physical therapy
Physical Therapy Modalities
Physiological aspects
Rehabilitation
rééducation motrice
Teaching
Therapeutics, Physiological
Up-Regulation - physiology
Canada
exercice physique
BDNF
rééducation motrice
maladie de Parkinson
motor rehabilitation
physical exercise
Parkinson’s disease
Online AccessGet full text

Cover

Abstract Increasing evidence suggests that motor rehabilitation may delay Parkinson’s disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30–T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III – Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.
AbstractList Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/ month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30-T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III - Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.
Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/ month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30-T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III - Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action. Key words: motor rehabilitation, physical exercise, BDNF, Parkinson's disease. De plus en plus de donnees suggerent que la reeducation motrice peut retarder la progression de la maladie de Parkinson (MP). De plus, des traitements paralleles chez l'animal regulent a la hausse l'expression du facteur de croissance neurotrophique derive du cerveau BDNF. Ainsi, les auteurs ont etudie l'effet d'un protocole de reeducation motrice sur les symptomes de la MP et sur les niveaux seriques de BDNF. La reeducation motrice consistait en un cycle de 20 jours/mois de physiotherapie repartie en 3 sessions quotidiennes. Les donnees cliniques ont ete recoltees au debut, a la fin et au jour 90 en post-observation. Les niveaux seriques de BDNF ont ete mesures par ELISA a 0, 7,14, 30 et 90 jours. La periode post- observation avait une duree de 60 jours, (J30 cl J90). Les resultats ont montre qu'a la fin du traitement (J30), une amelioration des signes extrapyramidaux (echelle UPDRS III ; les items demarche et equilibre de l'echelle UPDRS III), des activites motrices (marche de 6 minutes) et quotidiennes (echelle UPDRS II; questionnaire PDQ-39) etait observee. Les niveaux de BDNF augmentaient au jour 7 comparativement au niveau de base, apres quoi, aucun changement des niveaux de BDNF n'etait observe durant le traitement et lors de la periode post-observation subsequente. Cette etude demontre que la reeducation motrice peut ameliorer les symptomes de la MP et accroitre temporairement les niveaux seriques de BDNF. Ce dernier effet peut potentiellement contribuer a l'action therapeutique observee. [Traduit par la Redaction] Mots-cles: reeducation motrice, exercice physique, BDNF, maladie de Parkinson.
Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30-T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III - Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.Original Abstract: De plus en plus de donnees suggerent que la reducation motrice peut retarder la progression de la maladie de Parkinson (MP). De plus, des traitements paralleles chez l'animal regulent a la hausse l'expression du facteur de croissance neurotrophique derive du cerveau BDNF. Ainsi, les auteurs ont etudie l'effet d'un protocole de reducation motrice sur les symptomes de la MP et sur les niveaux seriques de BDNF. La reducation motrice consistait en un cycle de 20 jours/mois de physiotherapie repartie en 3 sessions quotidiennes. Les donnees cliniques ont ete recoltees au debut, a la fin et au jour 90 en post-observation. Les niveaux seriques de BDNF ont ete mesures par ELISA a 0, 7, 14, 30 et 90 jours. La periode post-observation avait une duree de 60 jours, (J30 a J90). Les resultats ont montre qu'a la fin du traitement (J30), une amelioration des signes extrapyramidaux (echelle UPDRS III ; les items demarche et equilibre de l'echelle UPDRS III), des activites motrices (marche de 6 minutes) et quotidiennes (echelle UPDRS II ; questionnaire PDQ-39) etait observee. Les niveaux de BDNF augmentaient au jour 7 comparativement au niveau de base, apres quoi, aucun changement des niveaux de BDNF n'etait observe durant le traitement et lors de la periode post-observation subsequente. Cette etude demontre que la reducation motrice peut ameliorer les symptomes de la MP et accroitre temporairement les niveaux seriques de BDNF. Ce dernier effet peut potentiellement contribuer a l'action therapeutique observee. [Traduit par la Redaction]
Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30-T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III - Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate brain-derived neurotrophic factor (BDNF). Thus, we investigated the effect of a motor rehabilitation protocol on PD symptoms and BDNF serum levels. Motor rehabilitation training consisted of a cycle of 20 days/month of physiotherapy divided in 3 daily sessions. Clinical data were collected at the beginning, at the end, and at 90 days follow-up. BDNF serum levels were detected by ELISA at 0, 7, 14, 21, 30, and 90 days. The follow-up period had a duration of 60 days (T30-T90). The results showed that at the end of the treatment (day 30), an improvement in extrapyramidal signs (UPDRS III; UPDRS III - Gait and Balance items), motor (6 Minute Walking Test), and daily living activities (UPDRS II; PDQ-39) was observed. BDNF levels were increased at day 7 as compared with baseline. After that, no changes in BDNF were observed during the treatment and in the successive follow-up. This study demonstrates that motor rehabilitation training is able to ameliorate PD symptoms and to increase temporarily BDNF serum levels. The latter effect may potentially contribute to the therapeutic action.
Abstract_FL De plus en plus de données suggèrent que la rééducation motrice peut retarder la progression de la maladie de Parkinson (MP). De plus, des traitements parallèles chez l’animal régulent à la hausse l’expression du facteur de croissance neurotrophique dérivé du cerveau BDNF. Ainsi, les auteurs ont étudié l’effet d’un protocole de rééducation motrice sur les symptômes de la MP et sur les niveaux sériques de BDNF. La rééducation motrice consistait en un cycle de 20 jours/mois de physiothérapie répartie en 3 sessions quotidiennes. Les données cliniques ont été récoltées au début, à la fin et au jour 90 en post-observation. Les niveaux sériques de BDNF ont été mesurés par ELISA à 0, 7, 14, 30 et 90 jours. La période post-observation avait une durée de 60 jours, (J30 à J90). Les résultats ont montré qu’à la fin du traitement (J30), une amélioration des signes extrapyramidaux (échelle UPDRS III ; les items démarche et équilibre de l’échelle UPDRS III), des activités motrices (marche de 6 minutes) et quotidiennes (échelle UPDRS II ; questionnaire PDQ-39) était observée. Les niveaux de BDNF augmentaient au jour 7 comparativement au niveau de base, après quoi, aucun changement des niveaux de BDNF n’était observé durant le traitement et lors de la période post-observation subséquente. Cette étude démontre que la rééducation motrice peut améliorer les symptômes de la MP et accroitre temporairement les niveaux sériques de BDNF. Ce dernier effet peut potentiellement contribuer à l’action thérapeutique observée. [Traduit par la Rédaction]
Audience Academic
Author Tramontano, Marco
Angelucci, Francesco
Gelfo, Francesca
Piermaria, Jacopo
Fiore, Marco
Caltagirone, Carlo
Shofany, Jacob
Peppe, Antonella
Author_xml – sequence: 1
  givenname: Francesco
  surname: Angelucci
  fullname: Angelucci, Francesco
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 2
  givenname: Jacopo
  surname: Piermaria
  fullname: Piermaria, Jacopo
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 3
  givenname: Francesca
  surname: Gelfo
  fullname: Gelfo, Francesca
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 4
  givenname: Jacob
  surname: Shofany
  fullname: Shofany, Jacob
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 5
  givenname: Marco
  surname: Tramontano
  fullname: Tramontano, Marco
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 6
  givenname: Marco
  surname: Fiore
  fullname: Fiore, Marco
  organization: Institute of Cellular Biology and Neurobiology, CNR, Via del Fosso di Fiorano 64, 00143 Rome, Italy
– sequence: 7
  givenname: Carlo
  surname: Caltagirone
  fullname: Caltagirone, Carlo
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
– sequence: 8
  givenname: Antonella
  surname: Peppe
  fullname: Peppe, Antonella
  organization: Department of Clinical and Behavioural Neurology, IRCCS Santa Lucia Foundation, Via Ardeatina 354, 00142 Rome, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26863448$$D View this record in MEDLINE/PubMed
BookMark eNqVkkFvFCEUxyemxm6rV4-G6EUPU4FhZphjrVabNNVoPROGeeyyMrCFGePe_Bp-PT-JTLpat1nTGA484Pd_Dx7_g2zPeQdZ9pjgI0KK5qVarlY5xaTMcUHpvWxGKC7zumRkL5thjHnOKKH72UGMy7SseMEfZPu04lXBGJ9l68sFINAa1BCR16j3gw8owEK2xppBDsY7NARpnHFzlGJlU6ikRXHdrwbfRyRdhyKEsUevXl-cIgtfwUZkHPogwxfjonc_v_-IqDMRZAQUx3Y5VXuY3dfSRni0mQ-zz6dvLk_e5efv356dHJ_nqsZsyJXkmtKmLSjWjCvKCGiMm1ZCOm6Zho5QVpOW0pZhQruOkxJ0V7Ztx-qiksVh9vw67yr4qxHiIHoTFVgrHfgxCsIJaTBvmuJutK4bzquaTOizW-jSj8GlhySKM8KqijY31FxaEMZpn1qppqTimJWkYaSqcaLyHdQcHARp03drk7a3-Kc7eLUyV-Jv6GgHlEYHvVE7s77YEiRmgG_DXI4xirNPH_-Dvdhmn2w6NbY9dGIVTC_DWvz24M1NVfAxBtB_EILFZHIxmVxMJheTyZOA3RKojVMno9p_y8i1zAUVIJkxqMVdpX4B2LIM9g
CODEN CJPPA3
CitedBy_id crossref_primary_10_2174_1871530322666220704101310
crossref_primary_10_1155_2017_2138169
crossref_primary_10_1590_1809_2950_17012926022019
crossref_primary_10_3390_ijms19113650
crossref_primary_10_1007_s12017_016_8407_9
crossref_primary_10_1080_00207454_2017_1288623
crossref_primary_10_3390_biomedicines11041174
crossref_primary_10_1016_j_physbeh_2020_113135
crossref_primary_10_2174_1568026623666230222094517
crossref_primary_10_3390_microorganisms11040925
crossref_primary_10_1155_2020_8961493
crossref_primary_10_1186_s13052_023_01466_z
crossref_primary_10_3390_ijerph18189528
crossref_primary_10_3390_antiox11010145
crossref_primary_10_3389_fnagi_2017_00358
crossref_primary_10_3390_cells12040655
crossref_primary_10_2174_1871527320666211201154839
crossref_primary_10_1016_j_exger_2021_111384
crossref_primary_10_1016_j_neubiorev_2022_105015
crossref_primary_10_1097_TGR_0000000000000276
crossref_primary_10_3390_cimb45110562
crossref_primary_10_3389_fnins_2023_1237726
crossref_primary_10_1097_MRR_0000000000000291
crossref_primary_10_3390_brainsci13030437
crossref_primary_10_1515_revneuro_2017_0040
crossref_primary_10_3390_diagnostics12051162
crossref_primary_10_1016_j_actpha_2016_11_024
crossref_primary_10_1080_13825585_2019_1617396
crossref_primary_10_1139_apnm_2018_0427
crossref_primary_10_1007_s43440_020_00120_3
crossref_primary_10_1038_nrneurol_2017_128
crossref_primary_10_1186_s40035_018_0112_1
crossref_primary_10_3233_RNN_170744
crossref_primary_10_1016_j_ijporl_2017_12_014
crossref_primary_10_1155_2016_1732163
crossref_primary_10_1016_j_arr_2023_102089
crossref_primary_10_3390_brainsci14030194
crossref_primary_10_23736_S2724_606X_21_04687_6
crossref_primary_10_1016_j_ejogrb_2020_01_046
crossref_primary_10_1155_2017_4716197
crossref_primary_10_3389_fphys_2024_1352305
crossref_primary_10_1016_j_jns_2020_117022
crossref_primary_10_1016_j_npep_2023_102357
Cites_doi 10.1016/S0304-3940(02)00529-3
10.1007/BF02260863
10.1016/j.gaitpost.2013.10.019
10.1227/00006123-199510000-00018
10.3233/NRE-131020
10.1038/350230a0
10.1002/mds.22571
10.1016/j.apmr.2013.03.029
10.1016/0022-3956(75)90026-6
10.1016/j.semcdb.2011.07.002
10.1002/mds.10473
10.2165/11534530-000000000-00000
10.1177/1545968313508474
10.1136/jnnp-2013-306787
10.1096/fj.12-220418
10.1016/0169-328X(95)00250-V
10.1002/mds.20213
10.1016/j.neurobiolaging.2010.11.010
10.1097/PHM.0b013e31828cd254
10.1113/expphysiol.2009.048512
10.1097/00001756-199902250-00021
10.1073/pnas.91.11.5104
10.1016/j.gaitpost.2006.11.207
10.1016/j.neuroscience.2013.02.063
10.1016/S0028-3908(98)00141-5
10.4103/0972-2327.144311
10.1177/1545968310380926
10.1038/nn.2505
10.1002/mds.23316
10.7861/clinmedicine.13-1-93
10.3390/ijerph8124702
10.1007/7854_2012_231
10.1093/ageing/afu010
10.1016/S0304-3940(99)00463-2
10.1016/j.euroneuro.2008.07.008
10.1155/2015/917085
10.1016/j.neurobiolaging.2004.03.002
10.1016/j.parkreldis.2015.09.005
10.1001/archneur.56.1.33
10.1007/s10571-009-9458-3
10.1124/pr.111.005678
10.1111/j.1460-9568.2011.07626.x
10.1016/j.pmrj.2013.05.019
10.1007/s00415-009-5357-2
10.1007/s11136-011-0026-1
10.1016/j.physio.2012.06.004
10.1002/14651858.CD007830
10.1002/14651858.CD002817
10.1097/JCP.0b013e3181fc2ec7
10.1023/A:1026025408742
10.1007/s00702-012-0876-x
10.1155/2012/719167
10.1523/JNEUROSCI.15-12-07810.1995
ContentType Journal Article
Copyright COPYRIGHT 2016 NRC Research Press
Copyright Canadian Science Publishing NRC Research Press Apr 2016
Copyright_xml – notice: COPYRIGHT 2016 NRC Research Press
– notice: Copyright Canadian Science Publishing NRC Research Press Apr 2016
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISN
ISR
7QP
7QR
7TK
8FD
FR3
K9.
NAPCQ
P64
7X8
7TS
DOI 10.1139/cjpp-2015-0322
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Canada
Gale In Context: Science
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Physical Education Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Physical Education Index
DatabaseTitleList

CrossRef

Neurosciences Abstracts
MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
Physical Therapy
EISSN 1205-7541
EndPage 461
ExternalDocumentID 4034892291
A451941670
26863448
10_1139_cjpp_2015_0322
cjpp-2015-0322
Genre Research Support, Non-U.S. Gov't
Journal Article
Feature
GeographicLocations Canada
GeographicLocations_xml – name: Canada
GroupedDBID -
08R
0R
1AW
29B
2QV
3O-
3V.
4.4
53G
55
5GY
5RE
5RP
7RV
7X7
88A
88E
88I
8AF
8AO
8FE
8FH
8FI
8FJ
8FQ
AALRV
ABDBF
ABFLS
ABPTK
ABUFD
ABUWG
ACGFS
ACGOD
ACIWK
ACKIV
ACPRK
ADBBV
ADKZR
AENEX
AFFNX
AFKRA
AFRAH
AHMBA
AJYGW
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBAFP
BBNVY
BCGST
BCR
BENPR
BES
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CAG
COF
CS3
D8U
DU5
DWQXO
DXH
EAD
EAP
EAS
EBD
EBS
ECC
EDH
EJD
EMB
EMK
EPL
ESX
EX3
F5P
FYUFA
GJ
GNUQQ
HCIFZ
HZ
IAO
ICQ
IEA
IHR
INH
INR
IOF
IPY
ISN
ISR
ITC
L7B
LK8
M0L
M1P
M2P
M2Q
M3C
M3E
M3G
M7P
MV1
MVM
NMEPN
NRXXU
NYCZX
O9-
OVD
P2P
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
QF4
QM4
QN7
QO4
QRP
RIG
RRCRK
RRP
SV3
TUS
UAP
WH7
WOW
X
X7M
ZGI
ZXP
---
-~X
.55
.GJ
00T
0R~
36B
6J9
AAYXX
ABJNI
ACGFO
ACUHS
AIAGR
ALIPV
CCPQU
CITATION
DATHI
EMOBN
HMCUK
HZ~
IPNFZ
MK0
NAPCQ
ONR
PHGZM
PHGZT
PPXIY
PQGLB
PV9
RZL
TEORI
UKHRP
VQG
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
8FD
FR3
K9.
P64
7X8
7TS
ID FETCH-LOGICAL-c704t-ca8f229b320f48c241ef009bae704b4fed12471b22b4012dd815efd5bbd4736a3
ISSN 0008-4212
1205-7541
IngestDate Fri Jul 11 07:29:35 EDT 2025
Fri Jul 11 05:42:16 EDT 2025
Sat Aug 16 03:01:03 EDT 2025
Tue Mar 18 23:44:35 EDT 2025
Fri Mar 14 03:11:51 EDT 2025
Tue Jun 10 15:32:46 EDT 2025
Sat Mar 08 18:49:06 EST 2025
Wed Mar 05 05:11:56 EST 2025
Wed Mar 05 04:36:00 EST 2025
Thu Apr 03 06:56:31 EDT 2025
Thu Jul 10 07:30:12 EDT 2025
Thu Apr 24 23:09:01 EDT 2025
Wed Nov 11 00:34:19 EST 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords exercice physique
BDNF
rééducation motrice
maladie de Parkinson
motor rehabilitation
physical exercise
Parkinson’s disease
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c704t-ca8f229b320f48c241ef009bae704b4fed12471b22b4012dd815efd5bbd4736a3
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://utoronto.scholaris.ca/bitstreams/1ad32751-458a-40fe-ac65-755a840bc456/download
PMID 26863448
PQID 1784146629
PQPubID 47727
PageCount 7
ParticipantIDs nrcresearch_primary_10_1139_cjpp_2015_0322
gale_infotracmisc_A451941670
gale_infotracacademiconefile_A451941670
gale_incontextgauss_ISN_A451941670
gale_incontextgauss_ISR_A451941670
pubmed_primary_26863448
crossref_primary_10_1139_cjpp_2015_0322
crossref_citationtrail_10_1139_cjpp_2015_0322
proquest_miscellaneous_1779886713
proquest_miscellaneous_1811908993
gale_infotracgeneralonefile_A451941670
proquest_journals_1784146629
gale_infotraccpiq_451941670
PublicationCentury 2000
PublicationDate 2016-04-01
PublicationDateYYYYMMDD 2016-04-01
PublicationDate_xml – month: 04
  year: 2016
  text: 2016-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Canada
PublicationPlace_xml – name: Canada
– name: Ottawa
PublicationTitle Canadian journal of physiology and pharmacology
PublicationTitleAlternate Can J Physiol Pharmacol
PublicationYear 2016
Publisher NRC Research Press
Canadian Science Publishing NRC Research Press
Publisher_xml – name: NRC Research Press
– name: Canadian Science Publishing NRC Research Press
References refg47/ref47
refg40/ref40
refg22/ref22
refg36/ref36
refg51/ref51
refg11/ref11
refg25/ref25
refg6/ref6
refg15/ref15
refg29/ref29
refg43/ref43
refg26/ref26
refg5/ref5
Schmolesky M.T. (refg46/ref46) 2013; 12
refg54/ref54
refg37/ref37
refg19/ref19
refg21/ref21
refg7/ref7
refg4/ref4
refg48/ref48
refg10/ref10
refg1/ref1
refg32/ref32
Goetz C.G. (refg60/ref60) 2004; 19
refg35/ref35
refg53/ref53
refg42/ref42
refg24/ref24
refg16/ref16
refg50/ref50
refg13/ref13
refg56/ref56
refg20/ref20
refg38/ref38
refg45/ref45
refg49/ref49
refg31/ref31
refg9/ref9
refg34/ref34
refg52/ref52
refg8/ref8
refg2/ref2
Levivier M. (refg27/ref27) 1995; 15
refg23/ref23
refg17/ref17
refg30/ref30
Gazewood J.D. (refg14/ref14) 2013; 87
refg12/ref12
refg28/ref28
refg41/ref41
refg55/ref55
refg39/ref39
refg3/ref3
Guyatt G.H. (refg18/ref18) 1985; 132
refg44/ref44
refg33/ref33
References_xml – ident: refg23/ref23
  doi: 10.1016/S0304-3940(02)00529-3
– ident: refg40/ref40
  doi: 10.1007/BF02260863
– ident: refg6/ref6
  doi: 10.1016/j.gaitpost.2013.10.019
– ident: refg49/ref49
  doi: 10.1227/00006123-199510000-00018
– ident: refg7/ref7
  doi: 10.3233/NRE-131020
– volume: 12
  start-page: 502
  issue: 3
  year: 2013
  ident: refg46/ref46
  publication-title: J. Sports Sci. Med.
– ident: refg21/ref21
  doi: 10.1038/350230a0
– ident: refg52/ref52
  doi: 10.1002/mds.22571
– ident: refg39/ref39
  doi: 10.1016/j.apmr.2013.03.029
– ident: refg8/ref8
  doi: 10.1016/0022-3956(75)90026-6
– ident: refg5/ref5
  doi: 10.1016/j.semcdb.2011.07.002
– ident: refg35/ref35
  doi: 10.1002/mds.10473
– ident: refg25/ref25
  doi: 10.2165/11534530-000000000-00000
– ident: refg11/ref11
  doi: 10.1177/1545968313508474
– ident: refg13/ref13
  doi: 10.1136/jnnp-2013-306787
– ident: refg33/ref33
  doi: 10.1096/fj.12-220418
– ident: refg41/ref41
  doi: 10.1016/0169-328X(95)00250-V
– volume: 19
  start-page: 1020
  issue: 9
  year: 2004
  ident: refg60/ref60
  publication-title: Mov. Disord.
  doi: 10.1002/mds.20213
– volume: 132
  start-page: 919
  issue: 8
  year: 1985
  ident: refg18/ref18
  publication-title: Can. Med. Assoc. J.
– ident: refg56/ref56
  doi: 10.1016/j.neurobiolaging.2010.11.010
– ident: refg10/ref10
  doi: 10.1097/PHM.0b013e31828cd254
– ident: refg43/ref43
  doi: 10.1113/expphysiol.2009.048512
– ident: refg37/ref37
  doi: 10.1097/00001756-199902250-00021
– volume: 87
  start-page: 267
  issue: 4
  year: 2013
  ident: refg14/ref14
  publication-title: Am. Fam. Physician
– ident: refg12/ref12
  doi: 10.1073/pnas.91.11.5104
– ident: refg38/ref38
  doi: 10.1016/j.gaitpost.2006.11.207
– ident: refg30/ref30
  doi: 10.1016/j.neuroscience.2013.02.063
– ident: refg36/ref36
  doi: 10.1016/S0028-3908(98)00141-5
– ident: refg47/ref47
  doi: 10.4103/0972-2327.144311
– ident: refg16/ref16
  doi: 10.1177/1545968310380926
– ident: refg22/ref22
  doi: 10.1038/nn.2505
– ident: refg9/ref9
  doi: 10.1002/mds.23316
– ident: refg54/ref54
  doi: 10.7861/clinmedicine.13-1-93
– ident: refg2/ref2
  doi: 10.3390/ijerph8124702
– ident: refg17/ref17
  doi: 10.1007/7854_2012_231
– ident: refg51/ref51
  doi: 10.1093/ageing/afu010
– ident: refg34/ref34
  doi: 10.1016/S0304-3940(99)00463-2
– ident: refg3/ref3
  doi: 10.1016/j.euroneuro.2008.07.008
– ident: refg4/ref4
  doi: 10.1155/2015/917085
– ident: refg28/ref28
  doi: 10.1016/j.neurobiolaging.2004.03.002
– ident: refg1/ref1
  doi: 10.1016/j.parkreldis.2015.09.005
– ident: refg15/ref15
  doi: 10.1001/archneur.56.1.33
– ident: refg19/ref19
  doi: 10.1007/s10571-009-9458-3
– ident: refg20/ref20
  doi: 10.1124/pr.111.005678
– ident: refg26/ref26
  doi: 10.1111/j.1460-9568.2011.07626.x
– ident: refg32/ref32
  doi: 10.1016/j.pmrj.2013.05.019
– ident: refg45/ref45
  doi: 10.1007/s00415-009-5357-2
– ident: refg55/ref55
  doi: 10.1007/s11136-011-0026-1
– ident: refg42/ref42
  doi: 10.1016/j.physio.2012.06.004
– ident: refg31/ref31
  doi: 10.1002/14651858.CD007830
– ident: refg53/ref53
– ident: refg48/ref48
  doi: 10.1002/14651858.CD002817
– ident: refg44/ref44
  doi: 10.1097/JCP.0b013e3181fc2ec7
– ident: refg24/ref24
  doi: 10.1023/A:1026025408742
– ident: refg29/ref29
  doi: 10.1007/s00702-012-0876-x
– ident: refg50/ref50
  doi: 10.1155/2012/719167
– volume: 15
  start-page: 7810
  issue: 12
  year: 1995
  ident: refg27/ref27
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.15-12-07810.1995
SSID ssj0006838
Score 2.3730006
Snippet Increasing evidence suggests that motor rehabilitation may delay Parkinson’s disease (PD) progression. Moreover, parallel treatments in animals up-regulate...
Increasing evidence suggests that motor rehabilitation may delay Parkinson's disease (PD) progression. Moreover, parallel treatments in animals up-regulate...
SourceID proquest
gale
pubmed
crossref
nrcresearch
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 455
SubjectTerms Activities of Daily Living
Aged
BDNF
Brain
Brain-derived neurotrophic factor
Brain-Derived Neurotrophic Factor - blood
Care and treatment
exercice physique
Female
Gait - physiology
Humans
maladie de Parkinson
Male
Mental health care
Middle Aged
Motor Activity - physiology
motor rehabilitation
Parkinson Disease - blood
Parkinson Disease - physiopathology
Parkinson's disease
Patient outcomes
physical exercise
Physical therapy
Physical Therapy Modalities
Physiological aspects
Rehabilitation
rééducation motrice
Teaching
Therapeutics, Physiological
Up-Regulation - physiology
Title The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson’s disease subjects
URI http://www.nrcresearchpress.com/doi/abs/10.1139/cjpp-2015-0322
https://www.ncbi.nlm.nih.gov/pubmed/26863448
https://www.proquest.com/docview/1784146629
https://www.proquest.com/docview/1779886713
https://www.proquest.com/docview/1811908993
Volume 94
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELai5NIeqjbpY5u0cqsqkbqhBds89rhJuk3aahXlIeWGsIFkqwTosqhKf3N_RMfYGFCT9HFBiBnAZj7GM2b8gdAbF7KqEYyclsNpbDEncayAu7E1cjnEx8SOorhm-5x6-6fs05l7trT0s1O1VC34O_HjxnUl_2NVOAZ2latk_8Gy5qJwAPbBvrAFC8P2r23cKciAp57Ph_Me97b5B4T8KtAug7y-Khb5leJnhqZWV8OdvelkeClLiOoKWbkaWi8M88vmM86wrLictym7Ia3hN-iQUNTzJS27U9HyY5sZ_LGspq2EmDXhMzgskRtPPZMjxryp5BV5YUQfk8s0755kBpbjizwF39acwrszGo7XKYRRi9V0sxvv1pmQmx7tmpLEXpGKcu6BJT9wq6FN-XNiu5bvKm6txuGrvyprYLOO92aKMfj3UYVKUlbxtSgAfo5r2ZSQdvxsagb2x8fh4d4k_HIw_dyX1uECsykLRoRIqoUVAkkNWUYr4529nYmJHLyAqshBd0STjMLt3_dv3guidChxP5sLTRB1cXu6VIdNJw_RA53v4LEC7yO0lGSraG2cRQC_a7yJDw1SVtHmocLJ9TY-aZcFltu1WougNfQdxFgDH-cproGP-8DHDfAx7DfAxw3wMcAS18DHEvhYAR_PMmyAv1ViDXvcwP4xOp18ONndt_QfRCzh22xhiShI4YlzSuyUBQKi1SSFpIJHCYg5S5MYwlvf4YRwBpFaHAeOm6Sxy3nMfOpF9AlazvIseYYwJB4QKbOY-i5hyUhGcTSGc1yeJh5NogGyGpOEQvdUdvQyrNNsOgqlCUNpwlCacIC2jH6hiGVu1XwtLRxKtpZMloOdR1VZhgfH03AsyaEgpfLtW5WOekpbWinNoW0i0ktwoIeSBa6nud7TFMXsW9iRbvak54oh_6bLbPQUYegSPfHbDmj_-Bg2GkyH2qGVoSPLJpjnkdEAvTJieRtZO5oleSV1JCej5zv0Dp3AceoKCNB5qt4X0xziBR5lLHh-dwPW0b3WmW2g5cW8Sl5AwrLgL_V7_gtmuESQ
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+motor+rehabilitation+training+on+clinical+symptoms+and+serum+BDNF+levels+in+Parkinson%27s+disease+subjects&rft.jtitle=Canadian+journal+of+physiology+and+pharmacology&rft.au=Angelucci%2C+Francesco&rft.au=Piermaria%2C+Jacopo&rft.au=Gelfo%2C+Francesca&rft.au=Shofany%2C+Jacob&rft.date=2016-04-01&rft.pub=Canadian+Science+Publishing+NRC+Research+Press&rft.issn=0008-4212&rft.eissn=1205-7541&rft.volume=94&rft.issue=4&rft.spage=455&rft_id=info:doi/10.1139%2Fcjpp-2015-0322&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4034892291
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-4212&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-4212&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-4212&client=summon